FR06C0009I2 - - Google Patents

Info

Publication number
FR06C0009I2
FR06C0009I2 FR06C0009C FR06C0009C FR06C0009I2 FR 06C0009 I2 FR06C0009 I2 FR 06C0009I2 FR 06C0009 C FR06C0009 C FR 06C0009C FR 06C0009 C FR06C0009 C FR 06C0009C FR 06C0009 I2 FR06C0009 I2 FR 06C0009I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR06C0009C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22622452&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR06C0009(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of FR06C0009I1 publication Critical patent/FR06C0009I1/fr
Application granted granted Critical
Publication of FR06C0009I2 publication Critical patent/FR06C0009I2/fr
Active legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Thermal Transfer Or Thermal Recording In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • Lubricants (AREA)
FR06C0009C 1993-12-21 2006-03-13 Active FR06C0009I2 (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17108393A 1993-12-21 1993-12-21
PCT/US1994/014236 WO1995017407A1 (en) 1993-12-21 1994-12-20 Tetrahydrofuran antifungals

Publications (2)

Publication Number Publication Date
FR06C0009I1 FR06C0009I1 (en:Method) 2006-05-19
FR06C0009I2 true FR06C0009I2 (en:Method) 2006-12-29

Family

ID=22622452

Family Applications (1)

Application Number Title Priority Date Filing Date
FR06C0009C Active FR06C0009I2 (en:Method) 1993-12-21 2006-03-13

Country Status (28)

Country Link
EP (1) EP0736030B1 (en:Method)
JP (1) JP2834889B2 (en:Method)
KR (1) KR0179990B1 (en:Method)
CN (1) CN1064685C (en:Method)
AT (1) ATE204875T1 (en:Method)
AU (1) AU681753B2 (en:Method)
BR (1) BR1100154B1 (en:Method)
CA (1) CA2179396C (en:Method)
CO (1) CO4520281A1 (en:Method)
CZ (1) CZ294823B6 (en:Method)
DE (2) DE69428125T2 (en:Method)
DK (1) DK0736030T3 (en:Method)
ES (1) ES2159623T3 (en:Method)
FI (1) FI118470B (en:Method)
FR (1) FR06C0009I2 (en:Method)
HU (1) HU225062B1 (en:Method)
IL (1) IL112081A (en:Method)
LU (1) LU91216I2 (en:Method)
MY (1) MY130217A (en:Method)
NL (1) NL300219I2 (en:Method)
NO (2) NO316173B1 (en:Method)
NZ (1) NZ278713A (en:Method)
PL (1) PL181193B1 (en:Method)
PT (1) PT736030E (en:Method)
SK (1) SK283035B6 (en:Method)
TW (1) TW377349B (en:Method)
WO (1) WO1995017407A1 (en:Method)
ZA (1) ZA9410142B (en:Method)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019983A1 (en) * 1994-01-24 1995-07-27 Janssen Pharmaceutica N.V. Watersoluble azole antifungals
MX9701229A (es) * 1995-06-02 1997-05-31 Schering Corp Antifungicos de tetrahidrofurano.
WO1997000255A1 (en) * 1995-06-19 1997-01-03 Schering Corporation Tetrahydrofuran antifungals
US5698557A (en) * 1995-06-19 1997-12-16 Schering Corporation Hydroxy-substituted antifungals
HUP9902115A3 (en) * 1995-12-20 2000-06-28 Schering Corp Process for preparation of hydrazides
US5834472A (en) * 1996-05-24 1998-11-10 Schering Corporation Antifungal composition with enhanced bioavailability
AU719109B2 (en) 1996-05-24 2000-05-04 Merck Sharp & Dohme Corp. Antifungal composition with enhanced bioavailability
KR20000022294A (ko) * 1996-06-28 2000-04-25 둘락 노먼 씨. 트리아졸 항진균 화합물을 함유하는 경구 조성물
US5846971A (en) * 1996-06-28 1998-12-08 Schering Corporation Oral antifungal composition
DE69730241T2 (de) * 1996-06-28 2005-08-11 Schering Corp. Feste lösung eines fungizids mit erhöhter bioverfügbarkeit
US5972381A (en) * 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
CN1237174A (zh) * 1996-11-12 1999-12-01 塞普拉科公司 2r,4s,s,r-和2s,4r,s,r-羟基伊曲康唑
CN1237172A (zh) * 1996-11-12 1999-12-01 塞普拉科公司 2r,4s,r,s-和2s,4r,r,s-羟基伊曲康唑-和羟基沙波康唑衍生物
WO1998021205A1 (en) * 1996-11-12 1998-05-22 Sepracor, Inc. 2r,4s,r,r- and 2s,4r,r,r-hydroxyitraconazole
EP0937071A1 (en) 1996-11-12 1999-08-25 Sepracor, Inc. 2r,4s,s,s- and 2s,4r,s,s-hydroxyitraconazole
US5684197A (en) * 1996-12-12 1997-11-04 Schering Corporation Process for preparation of hydrazides
JP4347911B2 (ja) 1997-02-11 2009-10-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アミノ酸エステル含有アゾール抗真菌剤
US6043245A (en) * 1997-09-25 2000-03-28 Schering Corporation Tetrahydrofuran antifungal phosphate
HUP0004616A3 (en) * 1997-09-25 2002-04-29 Schering Corp Hydroxy ester of tetrahydrofurane derivative as prodrug for the corresponding antifungal agent
WO1999018111A1 (en) * 1997-10-07 1999-04-15 Schering Corporation Crystalline antifungal glycine ester polymorph
DK1021439T3 (da) * 1997-10-07 2004-05-10 Schering Corp Krystallinsk antifungal polymorf form
US6713481B1 (en) * 1997-10-17 2004-03-30 David R. Andrews Crystalline antifungal polymorph
US5883097A (en) * 1998-04-16 1999-03-16 Schering Corporation Soluble azole antifungal salt
EP0957101A1 (en) 1998-05-14 1999-11-17 Janssen Pharmaceutica N.V. Water soluble azoles as broad-spectrum antifungals
US6147077A (en) * 1999-04-29 2000-11-14 Sepracor Inc. 2R,4S-hydroxyitraconazole isomers
KR20010094761A (ko) 1999-05-04 2001-11-01 디르크 반테 항진균 에테르
US6362172B2 (en) 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
US6448401B1 (en) 2000-11-20 2002-09-10 Bristol-Myers Squibb Company Process for water soluble azole compounds
EP2090165A3 (en) 2001-04-03 2012-03-28 Schering Corporation Antifungal composition with enhanced bioavailability
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
WO2003101392A2 (en) 2002-05-31 2003-12-11 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
JP4625637B2 (ja) 2002-02-22 2011-02-02 シャイア エルエルシー 活性物質送達系及び活性物質を保護し投与する方法
AU2003213719A1 (en) 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
AU2003243699B2 (en) 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
ITMI20032020A1 (it) 2003-10-17 2005-04-18 Italfarmaco Spa Nuovi agenti antifungini azolici con diminuita interazione con i citocromi metabolici
DK1776109T3 (da) * 2004-08-13 2009-05-04 Schering Plough Ltd Farmaceutisk formulering omfattende et antibiotikum, en triazol og et cortocosteroid
JO2691B1 (en) * 2005-05-03 2013-03-03 ايساي آر آند دي مانجمنت كو.، ليمتد Monolysine salts for azole compounds
EP2130540A1 (en) 2008-06-02 2009-12-09 Sandoz AG Pharmaceutical compositions containing a crystalline form of posaconazole
EP2141159A1 (en) 2008-07-03 2010-01-06 Sandoz AG A Crystalline form of posaconazole
CA2767489A1 (en) 2009-07-09 2011-01-13 Sandoz Ag A crystalline form of posaconazole
WO2011158248A2 (en) * 2010-05-12 2011-12-22 Glenmark Generics Limited Process for preparation of posaconazole and crystalline polymorphic form v of posaconazole
MX338514B (es) 2010-05-19 2016-04-20 Sandoz Ag Preparacion de intermediarios de posaconazol.
AU2011254654B2 (en) * 2010-05-19 2016-01-07 Sandoz Ag Process for the preparation of chiral triazolones
BR112012029225B1 (pt) 2010-05-19 2020-10-27 Sandoz Ag processo para a preparação de um composto quiral, composto quiral e uso de um composto quiral
JP5955837B2 (ja) 2010-05-19 2016-07-20 サンド・アクチエンゲゼルシヤフト ポサコナゾール及びポサコナゾール中間体の精製
DK3391890T3 (da) 2010-06-29 2021-11-01 Merck Sharp & Dohme Intravenøse posaconazolopløsningsformuleringer, der er stabiliseret ved hjælp af substitueret beta-cyclodextrin
CA2838051C (en) * 2011-06-16 2019-09-24 Sandoz Ag Process for the preparation of a chiral compound
EP2789610A1 (en) 2013-04-10 2014-10-15 Sandoz Ag Purification of Posaconazole Intermediates
CN105579448B (zh) * 2013-07-25 2018-12-21 桑多斯股份公司 制备泊沙康唑的晶型iv的改进方法
ITMI20132114A1 (it) 2013-12-18 2015-06-19 Djada Pharmaceutical Sa Una forma cristallina di posaconazolo
CN105287403A (zh) * 2014-08-02 2016-02-03 陕西合成药业股份有限公司 一种泊沙康唑前体药物的冻干组合物及其制备方法和用途
CN104370894A (zh) * 2014-10-21 2015-02-25 江苏恒盛药业有限公司 无定型泊沙康唑的制备工艺
ES2786374T3 (es) 2014-12-05 2020-10-09 Pulmocide Ltd Compuesto antimicótico
DK3298006T3 (da) 2015-05-21 2020-03-30 Pulmocide Ltd Antifungal 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-triazol-1-yl)methyl)-5-(2,4-difluorphenyl)tetrahydrofuran-3-yl)methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl)benzamid eller et farmaceutisk acceptabelt salt deraf
CN106317032A (zh) * 2015-06-15 2017-01-11 重庆圣华曦药业股份有限公司 一种制备高纯度的泊沙康唑的方法
CN106432338A (zh) * 2015-08-08 2017-02-22 陕西合成药业股份有限公司 泊沙康唑衍生物、合成和在长效制剂中的用途
ES2946734T3 (es) * 2015-09-23 2023-07-25 Biocon Ltd Formas cristalinas del intermedio de posaconazol y procedimiento para la preparación de posaconazol amorfo
CN105606736A (zh) * 2016-01-27 2016-05-25 重庆华邦制药有限公司 分离测定泊沙康唑中间体z1及其有关物质的方法
ES2893793T3 (es) * 2016-03-04 2022-02-10 Zhejiang Ausun Pharmaceutical Co Ltd Posaconazol, composición, producto intermedio, método de preparación para el mismo y usos del mismo
CN105949278B (zh) * 2016-03-30 2019-12-06 南京曼杰生物科技有限公司 一种取代的四氢呋喃水溶性衍生物及其应用
WO2017032908A1 (en) 2016-07-08 2017-03-02 Synthon B.V. Pharmaceutical composition comprising amorphous posaconazole
EP3558304A2 (en) 2016-12-23 2019-10-30 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
TR201620462A2 (tr) 2016-12-31 2018-07-23 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi POSAKONAZOL İÇEREN FARMASÖTİK BİLEŞİMLER ve ÜRETİM YÖNTEMİ
CN106967054A (zh) * 2017-03-30 2017-07-21 成都绿林科技有限公司 一种泊沙康唑的制备方法
CN106883221A (zh) * 2017-04-17 2017-06-23 兰州大学 一种无定形泊沙康唑及其制备方法
CN108341754A (zh) * 2018-03-12 2018-07-31 扬子江药业集团有限公司 泊沙康唑杂质及其制备方法和用途
CN110938093B (zh) * 2018-09-21 2022-08-19 华创合成制药股份有限公司 一种泊沙康唑磷酸酯单胆碱盐及其制备方法和用途
CN112778369B (zh) * 2019-11-05 2024-01-26 华创合成制药股份有限公司 一种三唑类衍生物及其制备方法和用途
CN113666915B (zh) * 2021-08-27 2022-08-16 江苏海洋大学 一种泊沙康唑中间体的制备方法
CN114315811B (zh) * 2021-11-19 2024-04-30 江苏恒盛药业有限公司 一种三氮唑类似物化合物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218458A (en) * 1978-06-23 1980-08-19 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxy-methyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (en) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derivatives of ¬¬4-¬4-(4-phenyl-1-piperazinyl)- phenoxymethyl|-1,3-dioxolan-2-yl|methyl|-1h-imidazoles and 1h-1,2,4-triazoles
EP0386143A1 (en) * 1987-11-20 1990-09-12 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
US5039676A (en) 1990-05-11 1991-08-13 Schering Corporation Tri- and tetra-substituted-oxetanes and tetrahydrofurans and intermediates thereof
IL103558A0 (en) * 1991-10-30 1993-03-15 Schering Corp Tri-substituted tetrahydrofuran antifungals

Also Published As

Publication number Publication date
HK1008820A1 (en) 1999-05-21
NO316173B1 (no) 2003-12-22
FR06C0009I1 (en:Method) 2006-05-19
EP0736030A1 (en) 1996-10-09
PL315169A1 (en) 1996-10-14
CZ180596A3 (en) 1997-01-15
PT736030E (pt) 2002-01-30
HUT75879A (en) 1997-05-28
DK0736030T3 (da) 2001-10-29
ATE204875T1 (de) 2001-09-15
DE69428125D1 (de) 2001-10-04
NZ278713A (en) 1997-12-19
DE122006000004I1 (de) 2006-04-27
IL112081A0 (en) 1995-03-15
ZA9410142B (en) 1996-05-02
WO1995017407A1 (en) 1995-06-29
JPH09500658A (ja) 1997-01-21
LU91216I2 (en) 2006-03-27
FI118470B (fi) 2007-11-30
NO962616D0 (no) 1996-06-20
NL300219I1 (nl) 2006-04-03
SK82696A3 (en) 1997-03-05
FI962577A0 (fi) 1996-06-20
SK283035B6 (sk) 2003-02-04
FI962577L (fi) 1996-06-20
CN1064685C (zh) 2001-04-18
TW377349B (en) 1999-12-21
CZ294823B6 (cs) 2005-03-16
PL181193B1 (pl) 2001-06-29
AU1512795A (en) 1995-07-10
CO4520281A1 (es) 1997-10-15
NO2006002I2 (no) 2011-03-07
BR1100154B1 (pt) 2013-11-26
EP0736030B1 (en) 2001-08-29
KR0179990B1 (en) 1999-03-20
ES2159623T3 (es) 2001-10-16
IL112081A (en) 2001-08-26
HU225062B1 (en) 2006-05-29
AU681753B2 (en) 1997-09-04
JP2834889B2 (ja) 1998-12-14
NO2006002I1 (no) 2006-02-20
HU9601709D0 (en) 1996-08-28
DE69428125T2 (de) 2002-05-02
CA2179396A1 (en) 1995-06-29
CA2179396C (en) 2001-04-17
NL300219I2 (nl) 2006-05-01
NO962616L (no) 1996-08-07
CN1142828A (zh) 1997-02-12
DE122006000004I2 (de) 2007-03-29
MY130217A (en) 2007-06-29

Similar Documents

Publication Publication Date Title
TW257915B (en:Method)
FR06C0009I2 (en:Method)
FR2706826B1 (en:Method)
FR2706813B1 (en:Method)
TW263567B (en:Method)
FR2702022B1 (en:Method)
EP0663652A3 (en:Method)
EP0757573A4 (en:Method)
FR04C0010I1 (en:Method)
IN184543B (en:Method)
EP0714291A4 (en:Method)
FR2706881B1 (en:Method)
FR2706852B1 (en:Method)
FR2705754B1 (en:Method)
EP0645942A3 (en:Method)
FR2706895B1 (en:Method)
EP0643239A3 (en:Method)
FR2702441B1 (en:Method)
FR2706906B1 (en:Method)
FR2706938B1 (en:Method)
TW282400B (en:Method)
FR2707037B1 (en:Method)
FR2706740B1 (en:Method)
FR2706752B3 (en:Method)
TW281719B (en:Method)